main
point
hydroxychloroquin
found
potent
chloroquin
inhibit
vitro
hydroxychloroquin
sulfat
mg
given
twice
daili
day
follow
mg
twice
daili
day
recommend
treat
infect
abstract
background
sever
acut
respiratori
syndrom
coronaviru
first
broke
wuhan
china
subsequ
spread
worldwid
chloroquin
sporad
use
treat
infect
hydroxychloroquin
share
mechan
action
chloroquin
toler
safeti
profil
make
prefer
drug
treat
malaria
autoimmun
condit
propos
immunomodulatori
effect
hydroxychloroquin
also
may
use
control
cytokin
storm
occur
latephas
critic
ill
infect
patient
current
evid
support
use
hydroxychloroquin
infect
method
pharmacolog
activ
chloroquin
hydroxychloroquin
test
use
infect
vero
cell
physiologicallybas
pharmacokinet
model
pbpk
implement
drug
separ
integr
vitro
data
use
pbpk
model
hydroxychloroquin
concentr
lung
fluid
simul
differ
dose
regimen
explor
effect
regimen
whilst
consid
drug
safeti
profil
result
hydroxychloroquin
found
potent
chloroquin
vitro
base
pbpk
model
result
load
dose
mg
twice
daili
hydroxychloroquin
sulfat
given
oral
follow
mainten
dose
mg
given
twice
daili
day
recommend
infect
reach
three
time
potenc
chloroquin
phosphat
given
mg
twice
daili
day
advanc
hydroxychloroquin
found
potent
chloroquin
inhibit
vitro
chloroquin
wide
use
antimalari
immunomodulatori
effect
recent
vitro
studi
chloroquin
found
inhibit
growth
vitro
find
support
clinic
studi
conduct
approxim
onehundr
infect
patient
hydroxychloroquin
analog
chloroquin
fewer
concern
drugdrug
interact
previou
sar
outbreak
hydroxychloroquin
report
antisarscov
activ
vitro
suggest
hydroxychloroquin
may
potenti
pharmacolog
agent
treatment
infect
howev
date
clinic
evid
support
use
hydroxychloroquin
treatment
infect
molecular
mechan
action
chloroquin
hydroxychloroquin
fulli
elucid
find
previou
studi
suggest
chloroquin
hydroxychloroquin
may
inhibit
coronaviru
seri
step
firstli
drug
chang
ph
surfac
cell
membran
thu
inhibit
fusion
viru
cell
membran
also
inhibit
nucleic
acid
replic
glycosyl
viral
protein
viru
assembl
new
viru
particl
transport
viru
releas
process
achiev
antivir
effect
reliabl
estim
hydroxychloroquin
chloroquin
concentr
lung
target
tissu
may
use
guid
dose
recommend
physiologicallybas
pharmacokinet
pbpk
model
mathemat
model
techniqu
predict
drug
concentr
human
tissu
silico
integr
physiolog
drug
disposit
paramet
pbpk
model
wide
use
drug
develop
help
identifi
whether
clinic
trial
warrant
well
help
guid
use
drug
base
predict
wellvalid
model
studi
aim
investig
antivir
prophylact
activ
hydroxychloroquin
chloroquin
vitro
ii
build
pbpk
model
hydroxychloroquin
chloroquin
use
data
literatur
iii
predict
drug
concentr
differ
dose
regimen
use
develop
pbpk
model
chloroquin
phosphat
hydroxychloroquin
sulfat
purchas
beij
innochem
scienc
technolog
co
ltd
lyophil
powder
dilut
doubl
distil
water
mm
hydroxychloroquin
sulfat
readili
solubl
water
chloroquin
phosphat
dissolv
shake
solut
room
temperatur
hour
chloroquin
hydroxychloroquin
solut
filter
membran
store
clinic
isol
viru
strain
ctanncov
wuhan
strain
propag
vero
cell
vero
cell
deriv
african
green
monkey
kidney
grown
dulbecco
modifi
eagl
medium
dmem
sigma
aldrich
boston
usa
supplement
fetal
bovin
serum
logan
ut
usa
cell
maintain
humidifi
atmospher
cultur
medium
replac
day
activ
chloroquin
hydroxychloroquin
investig
vitro
cell
seed
plate
densiti
cellswel
grown
hour
vitro
experi
divid
two
section
name
treatment
studi
ii
prophylact
studi
drug
pretreat
studi
vero
cell
pretreat
chloroquin
hydroxychloroquin
hour
remov
drugcontain
medium
viruscontain
medium
ad
infect
vero
cell
describ
treatment
studi
hour
follow
viruscontain
medium
remov
replac
fresh
medium
contain
drug
virus
supernat
collect
rna
extract
analyz
rel
quantif
use
rtpcr
method
describ
previous
publish
studi
experi
conduct
triplic
rel
express
estim
use
ct
method
sigmoid
concentrationrespons
function
ybottom
topbottom
hillslop
fit
data
use
nonlinear
regress
valu
calcul
use
prism
graphpad
softwar
san
diego
ca
usa
pbpk
model
chloroquin
hydroxychloroquin
develop
use
simcyp
simul
version
chloroquin
compound
file
provid
simcyp
limit
certara
compani
blade
enterpris
centr
sheffield
uk
hydroxychloroquin
compound
file
selfbuilt
physic
chemic
paramet
obtain
literatur
pharmacokinet
paramet
liver
intrins
clearanc
fa
ka
determin
clinic
data
data
summar
supplement
lung
blood
concentr
ratio
chloroquin
hydroxychloroquin
obtain
anim
studi
use
predict
drug
concentr
lung
publish
chloroquin
hydroxychloroquin
clinic
trial
data
use
valid
develop
pbpk
model
detail
summar
supplement
data
obtain
literatur
graphic
form
extract
use
plot
digit
version
getdata
pharmacokinet
paramet
could
sourc
literatur
estim
use
extract
data
phoenix
version
certara
compani
concentrationtim
profil
simul
differ
publish
clinic
trial
protocol
use
develop
pbpk
model
hydroxychloroquin
chloroquin
simcyp
healthi
volunt
chines
healthi
volunt
pediatr
virtual
popul
use
simul
clinic
trial
conduct
caucasian
chines
children
popul
respect
simul
exposur
data
compar
observ
data
criterion
determin
model
accuraci
base
whether
observ
data
fell
within
confid
interv
predict
valu
ratio
predict
pharmacokinet
pk
paramet
eg
cmax
auc
observ
valu
use
evalu
model
perform
predict
valu
consid
reason
ratio
predict
observ
data
within
rang
exposur
chloroquin
hydroxychloroquin
lung
plasma
blood
simul
differ
dose
regimen
shown
tabl
use
valid
pbpk
model
correct
factor
chloroquin
base
hydroxychloroquin
base
input
model
simul
chloroquin
phosphat
mg
equival
mg
chloroquin
base
mg
hydroxychloroquin
sulfat
equival
mg
hydroxychloroquin
base
chines
healthi
volunt
virtual
popul
provid
simcyp
use
simul
simul
perform
trial
subject
per
trial
virtual
subject
age
year
age
subject
male
femal
pbpk
model
use
predict
lung
tissu
concentr
chloroquin
hydroxychloroquin
differ
dose
regimen
tabl
lung
trough
concentr
day
adjust
plasma
unbound
fraction
fu
plasma
obtain
free
lung
trough
concentr
ratio
free
lung
trough
concentr
vitro
valu
rltec
calcul
result
tabul
recent
clinic
trial
mg
chloroquin
phosphat
given
twice
daili
shown
effect
studi
day
rltec
dose
regimen
chloroquin
use
target
dose
optim
hydroxychloroquin
ie
rltec
hydroxychloroquin
lower
rltec
chloroquin
time
result
vitro
studi
show
chloroquin
hydroxychloroquin
good
antivir
activ
chloroquin
hydroxychloroquin
found
decreas
viral
replic
concentrationdepend
manner
valu
chloroquin
hour
respect
figur
valu
hydroxychloroquin
hour
respect
figur
hydroxychloroquin
exhibit
superior
vitro
antivir
effect
comparison
chloroquin
drug
ad
prior
viral
challeng
valu
chloroquin
hour
respect
valu
hydroxychloroquin
hour
respect
note
longer
incub
time
valu
chloroquin
hydroxychloroquin
tend
decreas
inhibitori
effect
chloroquin
poor
particularli
evid
hour
wherebi
even
highest
concentr
chloroquin
use
studi
inhibit
rate
exceed
figur
predict
observ
plasmablood
concentr
time
profil
chloroquin
hydroxychloroquin
shown
figur
intraven
data
use
understand
distribut
elimin
phase
two
drug
oral
administr
data
use
understand
intracorpor
absorpt
process
observ
data
fell
within
predict
interv
ratio
predict
observ
pk
paramet
cmax
auc
within
rang
detail
summar
supplement
indic
predict
accuraci
develop
pbpk
model
accept
could
use
simul
differ
dose
scenario
simul
lung
blood
plasma
concentr
time
profil
chloroquin
hydroxychloroquin
differ
dose
regimen
shown
figur
seen
lung
blood
plasma
concentr
chloroquin
increas
slowli
first
dose
given
yet
reach
steadi
state
day
simul
chloroquin
concentr
lung
tissu
much
higher
plasma
lung
plasma
ratio
increas
time
reach
ratio
approxim
project
lung
blood
plasma
concentr
hydroxychloroquin
rapidli
increas
reach
steadi
state
follow
initi
load
dose
subsequ
mainten
dose
figur
free
lung
trough
concentr
also
project
simul
ratio
free
lung
trough
concentr
rltec
differ
dose
regimen
shown
tabl
rltec
valu
hydroxychloroquin
found
higher
rltec
valu
chloroquin
day
suggest
hydroxychloroquin
may
achiev
ideal
clinic
efficaci
simul
dose
regimen
rltec
day
notabl
higher
hydroxychloroquin
chloroquin
like
due
load
dose
hydroxychloroquin
given
thu
enabl
faster
clinic
effect
signific
differ
twice
daili
mainten
dose
regimen
regimen
c
respect
use
day
day
henc
daili
dose
regimen
may
prefer
improv
patient
complianc
despit
regimen
f
day
treatment
regimen
lung
trough
concentr
still
target
concentr
day
howev
treatment
durat
regimen
f
extend
day
ie
regimen
e
result
higher
drug
concentr
day
overal
regimen
f
may
best
regimen
whilst
consid
efficaci
safeti
patient
complianc
studi
hydroxychloroquin
exhibit
better
vitro
activ
chloroquin
demonstr
valu
hydroxychloroquin
alway
smaller
valu
chloroquin
indic
hydroxychloroquin
potent
antivir
activ
shown
figur
studi
wang
et
al
chloroquin
shown
inhibitori
effect
valu
hour
incub
time
find
compar
vitro
chloroquin
result
valu
addit
unpublish
clinic
trial
demonstr
therapeut
effect
chloroquin
infect
patient
basi
hydroxychloroquin
superior
antivir
prophylact
activ
well
toler
safeti
profil
comparison
chloroquin
believ
hydroxychloroquin
may
promis
drug
treatment
infect
studi
note
valu
hydroxychloroquin
chloroquin
decreas
longer
incub
time
suggest
incub
time
may
influenc
drug
antivir
activ
hydroxychloroquin
chloroquin
report
accumul
cell
possibl
longer
incub
time
may
provid
time
drug
accumul
higher
intracellular
concentr
ultim
exhibit
better
antivir
effect
anoth
possibl
explan
druginduc
cytotox
may
take
time
develop
henc
drug
effect
may
increas
time
pbpk
model
hydroxychloroquin
chloroquin
valid
vivo
pk
data
human
rat
mice
model
abl
reason
predict
drug
concentr
human
lung
tissu
permeabl
rate
limit
model
implement
pbpk
model
mimic
characterist
drug
addit
high
lung
plasma
partit
coeffici
ratio
kp
ratio
use
imit
drug
high
accumul
lung
tissu
kp
ratio
human
assum
ratio
rat
human
data
avail
assumpt
may
reason
transport
drug
complet
via
passiv
diffus
ie
transport
involv
patient
report
immun
respons
viru
result
increas
cytokin
may
progress
cytokin
storm
follow
multiorgan
failur
potenti
death
hydroxychloroquin
chloroquin
immunomodulatori
effect
suppress
increas
immun
factor
bear
mind
possibl
earli
treatment
either
drug
may
help
prevent
progress
diseas
critic
lifethreaten
state
critic
ill
infect
patient
use
corticosteroid
may
harm
whilst
use
immunosuppress
eg
tocilizumab
ideal
either
suppress
immun
system
lead
increas
risk
infect
set
hydroxychloroquin
may
ideal
drug
treat
infect
inhibit
viru
via
antivir
effect
help
mediat
cytokin
storm
via
immunomodulatori
effect
base
work
conduct
lab
recommend
concomit
use
low
dose
hydroxychloroquin
antiinflammatori
drug
help
mitig
cytokin
storm
critic
ill
patient
sever
clinic
trial
current
investig
use
hydroxychloroquin
treat
infect
howev
worth
note
dose
regimen
use
trial
mainli
base
previou
clinic
experi
rais
concern
advers
effect
may
occur
studi
particip
supplement
studi
optim
dose
regimen
design
hydroxychloroquin
high
load
dose
low
mainten
dose
base
uniqu
pharmacokinet
ie
high
accumul
cell
long
elimin
halflif
use
pbpk
model
simul
techniqu
optim
dose
regimen
hydroxychloroquin
evalu
silico
simul
result
demonstr
regimen
f
abl
achiev
treatment
efficaci
well
good
safeti
profil
even
consid
possibl
underestim
drug
efficaci
extent
howev
futur
clinic
trial
evalu
regimen
requir
readili
use
clinic
combin
vitro
antivir
activ
data
predict
drug
concentr
studi
use
support
design
dose
regimen
use
futur
clinic
trial
figur
antivir
activ
chloroquin
hydroxychloroquin
treatment
prophylact
treatment
vitro
antivir
activ
chloroquin
hydroxychloroquin
therapeut
prophylact
use
test
vero
cell
infect
clinic
isol
strain
b
treatment
group
chloroquin
hydroxychloroquin
ad
medium
vero
cell
infect
cell
incub
medium
contain
drug
hour
c
prophylact
treatment
group
vero
cell
pretreat
chloroquin
hydroxychloroquin
hour
virus
ad
medium
infect
cell
medium
remov
replac
fresh
medium
without
drug
virus
cell
incub
hour
viral
yield
cell
supernat
quantifi
rtpcr
